# EDGAR Filing Document

**Accession Number:** 0001729214
**File Stem:** 0001171843-26-001954
**Filing Date:** 2026-3
**Character Count:** 5638
**Document Hash:** 602a6d7ccbabb238d0dc61a000749959
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-001954.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001171843-26-001954

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260326

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XORTX Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001729214
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40858
- **FILM NUMBER:** 26800709

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 2400 - 745 THURLOW STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6E 0C5
- **BUSINESS PHONE:** 403-607-2621

**MAIL ADDRESS:**
- **STREET 1:** SUITE 2400 - 745 THURLOW STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6E 0C5

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**<br>

**For the month of March 2026** 

**Commission File Number: 001-40858**

**XORTX Therapeutics Inc.**

**3710 – 33<sup>rd</sup> Street NW, Calgary, Alberta, T2L 2M1**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F □

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **XORTX THERAPEUTICS INC.** | **XORTX THERAPEUTICS INC.** |
|  |  | (Registrant) | (Registrant) |
| Date: | March 26, 2026 | By: | */s/ Allen Davidoff* |
|  |  | Name: | Allen Davidoff |
|  |  | Title: | Chief Executive Officer<br>|

---

**<u>EXHIBIT INDEX</u>**

[99.1](exh_991.htm) [Report of Voting Results](exh_991.htm)

## Exhibit 99.1

**Exhibit 99.1**

**XORTX THERAPEUTICS INC.**

**Report of Voting Results**<br> (Section 11.3 of National Instrument 51-102)

In accordance with section 11.3 of National Instrument 51-102 - *Continuous Disclosure Obligations*, this report briefly describes the matters voted upon and the outcome of the votes at the Annual General and Special Meeting of Shareholders of XORTX Therapeutics Inc. (the "**Company**") held on March 24, 2026 at the offices of the Company (the "**Meeting**").

1. **Setting the Number of Directors at Seven** 

A resolution setting the number of directors of the board to five was approved. Proxies were received as follows:

---

| | |
|:---|:---|
| For the Motion: | 2,366,776 (98.323%) |
| Against: | 40,372 (1.677%) |

---

2. **Election of Directors** 

The shareholders voted by way of proxy and the following nominees were elected as directors to serve until the next annual meeting of shareholders of the Company or until their successors are duly elected or appointed:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Director** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Votes For** | **Votes Withheld** | **Votes Withheld** |
| Allen Davidoff | 709786 | 86.652% | 118900 | 14.348% |
| Mika Grasso | 2407148 | 100.000% | Nil |  |
| Anthony J. Giovinazzo | 775464 | 93.578% | 53.222 | 6.422% |
| Richard Grieve | 2407148 | 100.000% | Nil |  |
| George Scorsis | 2407148 | 100.000% | Nil |  |

---

3. **Appointment of Auditors** 

A resolution appointing Davidson & Co. LLP Chartered Professional Accountants as auditor of the Company until the next annual meeting of shareholders and authorizing the directors of the Company to fix the auditor's remuneration was approved. Proxies were received as follows:

---

| | |
|:---|:---|
| For the Motion: | 2,392,324 (99.384%) |
| Withheld: | 14,824 (0.616%) |

---

4. **Re-Approval of Stock Option Plan** 

A resolution re-approving and confirming the Company's stock option plan as described in the management information circular dated February 25, 2026, including that the maximum number of common shares reserved for issuance under the stock option plan at any given time is equal to ten percent (10%) of the issued and outstanding common shares as at the date of grant of an option under the stock option plan, was approved. Proxies were received as follows:

---

| | |
|:---|:---|
| For the Motion: | 705,839 (85.176%) |
| Against: | 122,847 (14.824%) |

---

5. **Share Consolidation** 

A resolution authorizing the Company to change the number of issued and outstanding common shares of the Company by consolidating the issued and outstanding common shares on the basis of up to five (5) pre-consolidation common shares for every one (1) post-consolidated common share in order for the Company to regain compliance with the continued listing requirements for the NASDAQ Capital Market. Proxies were received as follows:

---

| | |
|:---|:---|
| For the Motion: | 2,161,883 (89.811%) |
| Against: | 245,265 (49.697%) |

---

For additional information, please see the Company's notice of meeting and information circular dated February 25, 2026 filed on SEDAR+ in connection with the Meeting.

DATED at Calgary, AB, March 26, 2026.

---

| |
|:---|
| **XORTX THERAPEUTICS INC.**<br>*/s/ Charlotte May* |
| Charlotte May<br> Corporate Secretary |

---